ImmunoPrecise Antibodies

Custom Monoclonal and Polyclonal Antibody Development

Immunoprecise Antibodies Issues Letter to Shareholders

Life sciences technology and product company Immunoprecise has announced that its president Thomas D'Orazio has released a letter to shareholders to reflect on why he has also accepted the role...

Immunoprecise Antibodies Issues Letter to Shareholders

ImmunoPrecise's Rapid Prime System Ensures a 65-Day Completion of Hybridoma Development Programs

As a leading provider of custom monoclonal and polyclonal antibody development with over 20 years of experience, ImmunoPrecise Antibodies is well-positioned to offer some of the fastest...

ImmunoPrecise's Rapid Prime System Ensures a 65-Day Completion of Hybridoma Development Programs